Rhythm Pharmaceuticals (FRA:1RV) Cyclically Adjusted FCF per Share: €-2.41 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1RV Rhythm Pharmaceuticals Inc FRA:1RV
59 GF Score
Price €93.00
GF Value €93.47
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Rhythm Pharmaceuticals Cyclically Adjusted FCF per Share?

Rhythm Pharmaceuticals FRA:1RV -2.11% 59 Cyclically Adjusted FCF per Share is €-2.41 as of Jun. 2026. GuruFocus rates FRA:1RV with a GF Score™ of 59/100 and a GF Value™ of €93.47 (Fairly Valued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Rhythm Pharmaceuticals's adjusted free cash flow per share for the three months ended in Jun. 2026 was €-0.116. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-2.41 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-08-13), Rhythm Pharmaceuticals's current stock price is €93.00. Rhythm Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was €-2.41. Rhythm Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is .


Rhythm Pharmaceuticals  (FRA:1RV) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Rhythm Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms


Rhythm Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Rhythm Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rhythm Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Rhythm Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Rhythm Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -2.25 -2.41

FRA:1RV vs MIRM, COGT, ERAS: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Rhythm Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rhythm Pharmaceuticals Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rhythm Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Rhythm Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.


FRA:1RV
59GF Score
Rhythm Pharmaceuticals Inc FRA:1RV
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rhythm Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Rhythm Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.116/333.9520*333.9520
=-0.116

Current CPI (Jun. 2026) = 333.9520.

Rhythm Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -0.240 241.428 -0.332
201612 -0.350 241.432 -0.484
201703 -0.392 243.801 -0.537
201706 -0.210 244.955 -0.286
201709 -0.271 246.819 -0.367
201712 -0.244 246.524 -0.331
201803 -0.346 249.554 -0.463
201806 -0.382 251.989 -0.506
201809 -0.424 252.439 -0.561
201812 -0.536 251.233 -0.712
201903 -0.828 254.202 -1.088
201906 -0.716 256.143 -0.934
201909 -0.890 256.759 -1.158
201912 -0.686 256.974 -0.891
202003 -0.742 258.115 -0.960
202006 -0.599 257.797 -0.776
202009 -0.520 260.280 -0.667
202012 -0.541 260.474 -0.694
202103 -0.581 264.877 -0.733
202106 -0.613 271.696 -0.753
202109 -0.681 274.310 -0.829
202112 -0.714 278.802 -0.855
202203 -0.970 287.504 -1.127
202206 -0.805 296.311 -0.907
202209 -0.925 296.808 -1.041
202212 -0.570 296.797 -0.641
202303 -0.601 301.836 -0.665
202306 -0.754 305.109 -0.825
202309 -0.386 307.789 -0.419
202312 -0.455 306.746 -0.495
202403 -1.235 312.332 -1.320
202406 -0.443 314.175 -0.471
202409 -0.371 315.301 -0.393
202412 -0.292 315.605 -0.309
202503 -0.592 319.799 -0.618
202506 -0.317 322.561 -0.328
202509 -0.342 324.800 -0.352
202512 -0.324 324.054 -0.334
202603 -0.562 330.213 -0.568
202606 -0.116 333.952 -0.116

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-2.41 mean?
Rhythm Pharmaceuticals (FRA:1RV) has a Cyclically Adjusted FCF per Share of €-2.41 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Rhythm Pharmaceuticals and its competitors.
Is Rhythm Pharmaceuticals' Cyclically Adjusted FCF per Share too high?
Rhythm Pharmaceuticals' current Cyclically Adjusted FCF per Share is €-2.41. Overall, Rhythm Pharmaceuticals has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Rhythm Pharmaceuticals' Cyclically Adjusted FCF per Share compare to MIRM and COGT?
Rhythm Pharmaceuticals' Cyclically Adjusted FCF per Share of €-2.41 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Rhythm Pharmaceuticals and its competitors. Rhythm Pharmaceuticals's current Cyclically Adjusted FCF per Share is €-2.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Rhythm Pharmaceuticals (FRA:1RV) is currently considered Fairly Valued. The stock's GF Value™ is €93.47, compared to a current price of €93.00 — trading 0.5% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €-2.41. Rhythm Pharmaceuticals' overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Rhythm Pharmaceuticals (FRA:1RV), the current Cyclically Adjusted FCF per Share is €-2.41 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rhythm Pharmaceuticals (FRA:1RV) Overvalued in 2026?

Based on GuruFocus' analysis, Rhythm Pharmaceuticals stock appears to be undervalued. The current stock price of €93.00 is trading 0.5% below its estimated GF Value™ of €93.47. GuruFocus considers Rhythm Pharmaceuticals to be Fairly Valued.

Key valuation signals for FRA:1RV:

  • Cyclically Adjusted FCF per Share: €-2.41
  • GF Value™: €93.47 vs. price of €93.00 (0.5% below fair value)
  • GF Score™: 59/100 with 3 warning signs

No single metric tells the full story. See the FRA:1RV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Rhythm Pharmaceuticals Business Description

Other Exchanges RYTM:USA1RV:Germany
Address 222 Berkeley Street, 12th Floor, Boston, MA, USA, 02116
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
59GF Score

Get the complete analysis for FRA:1RV

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€93.00
Price
€93.47
GF Value